Instinct Bio has secured a 213 m² site in South Jakarta for its first GENRÊVER CLINIC and is targeting an opening by the end of December 2026. Monthly subscription tiers of $400, $1,000 and $3,000 give investors a defined pricing framework alongside the company’s cosmetic product development plans.
Key Highlights
- Monthly Jakarta clinic subscription plans are priced at $400, $1,000 and $3,000.
- Instinct Bio and Invitrx are targeting United States Manufacturing for a GENRÊVER cosmetic range within 2026.
- Instinct Bio has secured a 213 m² premises in South Jakarta’s Gandaria district, where interior construction has commenced.
Jakarta Clinic Construction and Subscription Structure
The Jakarta initiative includes three preliminary monthly subscription levels of $400, $1,000 and $3,000. The premises are located in the Gandaria district of South Jakarta, where interior work has commenced. Instinct (NASDAQ: BIOT) Bio said the clinic’s launch timing remains conditional on construction, permits and readiness to operate. The company said treatment availability will be governed by the applicable membership conditions, physician review, scheduling capacity and regulatory requirements.
GENRÊVER and HAKUA Product Development
PT Parva Candela and Instinct Bio have also identified two cosmetic candidates for Indonesia under the GENRÊVER and HAKUA brands.
FAQs
Q: When does Instinct Bio plan to open its Jakarta clinic?
A: Instinct Bio is targeting the first GENRÊVER CLINIC opening by the end of December 2026. Interior construction has commenced at a secured premises in South Jakarta.
Q: What are Instinct Bio’s Jakarta clinic subscription prices?
A: The preliminary GENRÊVER CLINIC subscription tiers are $400, $1,000 and $3,000 per month. These are preliminary rates for the Jakarta clinic, and treatment availability will depend on membership terms, physician assessment, scheduling capacity and applicable regulatory requirements.
Q: What products are Instinct Bio and PT Parva Candela developing for Indonesia?
A: The companies identified two initial cosmetic candidates for the Indonesian market under the GENRÊVER and HAKUA brands. The candidates are a premium UV cream and a moisturizing gel incorporating HA4 low-molecular-weight hyaluronic acid technology.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.